GE Healthcare has entered an agreement to exclusively provide next-generation sequencing services to a research group at Karolinska Institutet in Sweden. The services will be provided by GE Healthcare’s subsidiary, SeqWright Genomic Services, a Houston, TX-based provider of nucleic acid sequencing and other genomic services, acquired in 2012.
The first clinical study using the sequencing technology will focus on identifying mutations and genetic variants associated with metastatic breast cancer. KI will provide samples to be analyzed using GE’s next generation sequencing (NGS) capabilities.
“Understanding how genetic variations at the molecular level affect disease is critical to the discovery and development of new and more effective therapies for complex diseases such metastatic breast cancer,” said Ger Brophy, chief technology officer Life Sciences, GE Healthcare. “While antibody-based analysis of biomarkers are the cornerstone to diagnosing breast cancer, uncovering the broader molecular landscape of complex cancers using genome-wide screening tools such as NGS, will be critical to the future of therapeutic decision making and new therapeutic development.”